Ozmosi | FKC-288 Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

FKC-288

Alternative Names: FKC-288, FKC 288, FKC288
Clinical Status: Inactive
Latest Update: 2024-04-02
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: CAR-T, BCMA

Novel Mechanism: No

Modality: CAR-T (Unknown Type)

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Nanjing University School of Medicine
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Amyloidosis|Lupus Nephritis|Kidney Diseases|IgA Nephropathy|Glomerulonephritis, Membranous|Lupus Vasculitis|Membranous Nephropathy|ANCA Vasculitis|IgG4-related Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated
NJCT-2401

P1

Recruiting

Glomerulonephritis, Membranous|Lupus Nephritis|Kidney Diseases|IgA Nephropathy|ANCA Vasculitis|Membranous Nephropathy|IgG4-related Disease|Lupus Vasculitis

2026-12-31

2024-04-03

Primary Endpoints|Start Date|Treatments
NJCT-2301

P1

Recruiting

Amyloidosis

2025-06-01

2023-11-16

Primary Endpoints|Start Date|Treatments|Trial Status

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions